Arrowhead retains three directors who failed to win majority vote at 2022 annual meeting

ARROWHEAD PHARMACEUTICALS, INC.

Directors Perry, Ferrari, and Waddill each received less than a majority of votes for re-election on March 17, 2022.
The Nominating Committee and Board unanimously rejected their resignation offers, citing qualifications and board composition.
Primary reason for vote outcome was shareholder concern over executive compensation programs.
All three directors will continue serving until the 2023 annual meeting or until successors are elected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.